| Kathryn Latham Stoll, LMFT | |
|
125 Commerce St Ste B, Mccall, ID 83638-5192 | |
| (208) 634-2962 | |
| Not Available |
| Full Name | Kathryn Latham Stoll |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 125 Commerce St Ste B, Mccall, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558458869 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | MFC 40587 (California) | Secondary |
| 106H00000X | Marriage & Family Therapist | LMFT-6984 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn Latham Stoll, LMFT 125 Commerce St Ste B, Mccall, ID 83638-5192 Ph: (949) 395-2063 | Kathryn Latham Stoll, LMFT 125 Commerce St Ste B, Mccall, ID 83638-5192 Ph: (208) 634-2962 |
News Archive
Scientists at Duke University, North Carolina have developed a panel of tests which are able to analyze a cancerous tumor and then decide which chemotherapy will most efficiently attack the cancer.
What's the most common long-term complication of diabetes? Problems with the heart and blood vessels, according to the February issue of Mayo Clinic Women's HealthSource.
In an interview, Ardis Dee Hoven, the American Medical Association's new president, says that there is no formal role, but that the organization has been in touch with the Obama administration about how physicians can help patients get the information they need. Meanwhile, The Hill reports on a consumer survey that finds the health overhaul is not a consistent topic of conversation between doctors and patients.
Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.
British scientists say women who develop breast cancer because of two common genetic mutations could have their treatment transformed by a chemotherapy drug which already exists.
› Verified 5 days ago
Eric Mikkelsen, LAMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 321 N 3rd St, Mccall, ID 83638 Phone: 208-634-2962 |